This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morerio, C. Articles by Panarello, C. Search for Related Content PubMed PubMed Citation Articles by Morerio, C. Articles by Panarello, C.

HCMOGT-1 Is a Novel Fusion Partner to PDGFRB in Juvenile Myelomonocytic Leukemia with t(5;17)(q33;p11.2)

¹ Dipartimento di Ematologia ed Oncologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Istituto G. Gaslini, Genova; ² Oncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia; and ³ Sezione di Biologia e Genetica, Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Università dell’Insubria, Varese, Italy

PDGFRB, a transmembrane tyrosine kinase receptor for plateletderived growth factor, is constitutively activated by gene fusion with different partners in myeloproliferative/myelodysplastic disorders with peculiar clinical characteristics. Six alternative partner genes have been described thus far. In this study, we report the molecular cloning of a novel translocation t(5;17)(q33;p11.2) in a case of juvenile myelomonocytic leukemia. The novel partner gene was identified as HCMOGT-1 using 5'-rapid amplification of cDNA ends; fluorescence in situ hybridization and reverse transcriptase-PCR analyses confirmed that the translocation resulted in PDGFRB/HCMOGT-1 fusion. We show that the breakpoint of PDGFRB occurred at the same site of all previously reported PDGFRB translocations.

This article has been cited by other articles:

				S. Fletcher and B. Bain Eosinophilic leukaemia Br. Med. Bull., April 18, 2007; (2007) ldm008v1. [Abstract] [Full Text] [PDF]

				C. Walz, G. Metzgeroth, C. Haferlach, A. Schmitt-Graeff, A. Fabarius, V. Hagen, O. Prummer, S. Rauh, R. Hehlmann, A. Hochhaus, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor {beta} gene Haematologica, February 1, 2007; 92(2): 163 - 169. [Abstract] [Full Text] [PDF]

				S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF]

				B. Delaval, S. Letard, H. Lelievre, V. Chevrier, L. Daviet, P. Dubreuil, and D. Birnbaum Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome Cancer Res., August 15, 2005; 65(16): 7231 - 7240. [Abstract] [Full Text] [PDF]

				M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF]

				F. H. Grand, S. Burgstaller, T. Kuhr, E. J. Baxter, G. Webersinke, J. Thaler, A. J. Chase, and N. C. P. Cross p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor {beta} in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder Cancer Res., October 15, 2004; 64(20): 7216 - 7219. [Abstract] [Full Text] [PDF]